KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Intangibles (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Intangibles for 15 consecutive years, with $4.1 billion as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Intangibles changed N/A year-over-year to $4.1 billion, compared with a TTM value of $4.1 billion through Jun 2025, changed N/A, and an annual FY2024 reading of $4.4 billion, down 17.99% over the prior year.
  • Intangibles was $4.1 billion for Q2 2025 at Teva Pharmaceutical Industries, down from $4.4 billion in the prior quarter.
  • Across five years, Intangibles topped out at $8.1 billion in Q2 2021 and bottomed at $4.1 billion in Q2 2025.
  • Average Intangibles over 5 years is $6.1 billion, with a median of $6.0 billion recorded in 2023.
  • The sharpest move saw Intangibles decreased 14.08% in 2023, then decreased 17.99% in 2024.
  • Year by year, Intangibles stood at $7.5 billion in 2021, then dropped by 16.02% to $6.3 billion in 2022, then decreased by 14.08% to $5.4 billion in 2023, then dropped by 17.99% to $4.4 billion in 2024, then dropped by 6.25% to $4.1 billion in 2025.
  • Business Quant data shows Intangibles for TEVA at $4.1 billion in Q2 2025, $4.4 billion in Q4 2024, and $5.4 billion in Q4 2023.